Advantagene DBA Candel Therapeutics
Advantagene dba Candel Therapeutics is a Massachusetts based company developing an immunoncology platform technology, Gene Mediated Cytotoxic Immunotherapy (GMCI™), for the treatment of solid tumors. Advantagene''s active clinical trial for localized prostate cancer, the ProstAtak study (PrTK03), is a registration study under a FDA approved Special Protocol Assessment (SPA) for the treatment of localized prostate cancer patients with intermediate to high risk disease choosing radiation therapy as their first-line treatment. ProstAtak could become the first therapeutic pharmaceutical available for newly diagnosed, localized prostate cancer.
The immune system plays an important role in controlling cancer - but sometimes it needs help. GMCI™ is an immunotherapy mechanism that kills tumor cells and stimulates the immune system specifically against a patient''s own unique those same cancer cells systemically - beyond the tumor.
Advantagene also has GMCI™ clinical cancer studies in brain, lung and pancreas. For more information or to inquire about participation in the prostate trials please visit www.advantagene.com and contact us.
Brands: ProstAtak® being developed using GMCI™